Regen BioPharma, Inc.
RGBP
$0.00
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 236.70K | 236.70K | 236.70K | 236.70K | 236.70K |
| SG&A Expenses | 563.30K | 503.80K | 538.50K | 486.10K | 500.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 575.00K | 537.40K | 604.60K | 592.30K | 653.70K |
| Operating Income | -338.60K | -300.90K | -368.10K | -355.90K | -417.30K |
| Income Before Tax | -1.27M | -972.80K | -935.60K | -1.04M | -668.20K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.27 | -0.97 | -0.94 | -1.04 | -0.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.27M | -972.80K | -935.60K | -1.04M | -668.20K |
| EBIT | -338.60K | -300.90K | -368.10K | -355.90K | -417.30K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.04 | -0.05 | -0.05 | -0.06 | -0.04 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.03 |
| EPS Diluted | -0.04 | -0.05 | -0.05 | -0.06 | -0.04 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.03 |
| Average Basic Shares Outstanding | 173.10M | 125.13M | 94.48M | 67.81M | 65.75M |
| Average Diluted Shares Outstanding | 173.10M | 125.13M | 94.48M | 67.81M | 65.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |